Navigation Links
Blood sugar improves with first gastrointestinal microbiome modulator, NM504
Date:6/23/2014

CHICAGO, IL In adults with prediabetes, a new drug that alters microbial populations and their environment in the gastrointestinal (GI) tract improves glucose tolerancethe body's response to consuming carbohydrates after four weeks of treatment and without a change in diet. These results, from a pilot study, will be presented Monday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.

The not-yet-named therapeutic, NM504, is the first in a new class of therapies known as GI microbiome modulators. The GI microbiomethe mix of microbial and associated physical and chemical factors in the digestive systemmay play a critical part in regulating the body's metabolism, some researchers believe. There is recent scientific evidence that microbial imbalance, or dysbiosis, in the gut contributes to the development of Type 2 diabetes.

"We believe that modern Western diets contribute to development of Type 2 diabetes, in part because they change the habitat of the microorganisms that reside in the gut. This shifts the microbial populations that live there in ways that affect metabolic health," said Mark Heiman, PhD, the study's principal investigator. Heiman is chief scientific officer for MicroBiome Therapeutics, the Colorado-based biotechnology company that is developing NM504 and sponsored the study.

NM504 is designed to shift the GI bacteria and other microorganismscalled microbiotaand their environment in specific ways to achieve improved health outcomes, according to Heiman. He said the drug contains concentrated bioactive food ingredients: inulin, a fiber; beta-glucan and polyphenolic antioxidant compounds.

Heiman and colleagues conducted a study in 28 adults with prediabetes, a frequent precursor to Type 2 diabetes. Fourteen subjects were randomly assigned to receive NM504 twice a day, and the other 14 were assigned to receive placebo, or "dummy" material. Neither the subjects nor the investigators were aware of the drug assignments. Before any treatment and again at four weeks of treatment, all subjects had an oral glucose challenge. In this test, they drank a concentrated glucose (sugary) drink and then had their blood sugar levels tested at various times and compared with pretest levels.

Blood sugar levels at 120 and 180 minutes after the glucose challenge were significantly lower in subjects who took NM504 than those who received the placebo, Heiman reported. Also during this test, NM504 increased insulin sensitivity, the body's ability to successfully clear glucose from the bloodstream.

Compared with placebo, NM504 treatment also decreased the desire to eat, which Heiman said Microbiome Therapeutics' researchers had hoped the therapeutic would do. He said the subjects tolerated NM504 well, with only a mild increase in flatulence, or gas.

"This work indicates a new therapeutic targetthe GI microbiomethat has the potential to revolutionize the treatment of metabolic diseases such as Type 2 diabetes," Heiman commented.

MicroBiome Therapeutics reports that the company plans to develop NM504 and/or a closely related therapeutic as a prescription medicine to treat prediabetes and diabetes.


'/>"/>
Contact: Aaron Lohr
alohr@endocrine.org
202-971-3654
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Infection Might Raise Blood Clot Risk for Older Adults: Study
2. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
3. Common Blood Pressure Drug Safe for Heart Failure: Study
4. Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA
5. High Blood Pressure May Be Especially Lethal for Blacks
6. Changes in gene expression may help explain high blood pressure in pregnancy
7. Researchers Develop Blood Test for Depression
8. Naturopathic care can improve blood sugar, mood in diabetes
9. Diabetes Groups Issue New Guidelines on Blood Sugar
10. Exercise May Help Patients With High Blood Pressure Live Longer
11. Additional blood pressure screening may reduce incidence of CVD events and death by up to 3 percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
Breaking Medicine Technology: